NF-kappa B System Is Chronically Activated and Promotes Glomerular Injury in Experimental Type 1 Diabetic Kidney Disease

High glucose concentration can activate TLR4 and NF-kappa B, triggering the production of proinflammatory mediators. We investigated whether the NF-kappa B pathway is involved in the pathogenesis and progression of experimental diabetic kidney disease (DKD) in a model of long-term type 1 diabetes mellitus (DM). Adult male Munich-Wistar rats underwent DM by a single streptozotocin injection, and were kept moderately hyperglycemic by daily insulin injections. After 12 months, two subgroups - progressors and non-progressors - could be formed based on the degree of glomerulosclerosis. Only progressors exhibited renal TLR4, NF-kappa B and IL-6 activation. This scenario was already present in rats with short-term DM (2 months), at a time when no overt glomerulosclerosis can be detected. Chronic treatment with the NF-kappa B inhibitor, pyrrolidine dithiocarbamate (PDTC), prevented activation of renal TLR4, NF-kappa B or IL-6, without interfering with blood glucose. PDTC prevented the development of glomerular injury/inflammation and oxidative stress in DM rats. In addition, the NF-kappa B p65 component was detected in sclerotic glomeruli and inflamed interstitial areas in biopsy material from patients with type 1 DM. These observations indicate that the renal NF-kappa B pathway plays a key role in the development and progression of experimental DKD, and can become an important therapeutic target in the quest to prevent the progression of human DKD.

Palavras-chave

diabetic kidney disease, glomerulosclerosis, NF-kappa B, innate immunity, pyrrolidine dithiocarbamate

URI

https://observatorio.fm.usp.br/handle/OPI/35706

Referências

Arias SCA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056215
Anrather J, 2006, J BIOL CHEM, V281, P5657, DOI 10.1074/jbc.M506172200
Avila VF, 2019, HYPERTENS RES, V42, P779, DOI 10.1038/s41440-019-0226-6
DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873
Faustino VD, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180762
Foresto-Neto O, 2018, LAB INVEST, V98, P773, DOI 10.1038/s41374-018-0029-4
FUJIHARA CK, 1992, DIABETES, V41, P286, DOI 10.2337/diabetes.41.3.286
Fujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF92, DOI 10.1152/ajprenal.00184.2006
Gross JL, 2005, DIABETES CARE, V28, P164, DOI 10.2337/diacare.28.1.164
Gruden G, 2005, J AM SOC NEPHROL, V16, P688, DOI 10.1681/ASN.2004030251
Lee FTH, 2004, J AM SOC NEPHROL, V15, P2139, DOI 10.1097/01.ASN.0000135055.61833.A8
Lin M, 2012, J AM SOC NEPHROL, V23, P86, DOI 10.1681/ASN.2010111210
Molitch ME, 2004, DIABETES CARE, V27, P1240, DOI 10.2337/diacare.27.5.1240-a
Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
Okabe C, 2013, AM J PHYSIOL-RENAL, V305, pF155, DOI 10.1152/ajprenal.00491.2012
Rangan G, 2009, FRONT BIOSCI-LANDMRK, V14, P3496, DOI 10.2741/3467
Teles F, 2009, KIDNEY INT, V75, P72, DOI 10.1038/ki.2008.528
Utimura R, 2003, KIDNEY INT, V63, P209, DOI 10.1046/j.1523-1755.2003.00736.x
van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5
Verzola D, 2014, KIDNEY INT, V86, P1229, DOI 10.1038/ki.2014.116
WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1
Wang Y., 2016, J ASIAN CONCR FED, V2, P1, DOI 10.1155/2016/2543268
Wei MM, 2015, MOL IMMUNOL, V68, P261, DOI 10.1016/j.molimm.2015.09.002
Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0
YAN SD, 1994, J BIOL CHEM, V269, P9889
Yang PP, 2016, RENAL FAILURE, V38, P514, DOI 10.3109/0886022X.2016.1145515
ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521

Coleções

Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo